Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 2, 2008, Pages 330-337

  Cahlon, Oren ^a   Zelefsky, Michael J ^a   Shippy, Alison ^a   Chan, Heather ^a   Fuks, Zvi ^a   Yamada, Yoshiya ^a   Hunt, Margie ^a   Greenstein, Steven ^a   Amols, Howard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dose escalation; IMRT; Outcomes; Prostate cancer; Toxicity

Indexed keywords

DOSIMETRY; PATIENT MONITORING; RADIOTHERAPY; TOXICITY;

DOSE ESCALATION; PROSTATE CANCER; TISSUE CONSTRAINTS;

ONCOLOGY;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; UROGENITAL TRACT DISEASE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ERECTILE DYSFUNCTION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 43049168349     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.10.004     Document Type: Article

References (47)

1. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
4. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
5. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
6. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
7. Hanks G.E., Hanlon A.L., Epstein B., et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
8. Jacob R., Hanlon A.L., Horwitz E.M., et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100 (2004) 538-543
9. Pollack A., Hanlon A.L., Horwitz E.M., et al. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol 171 (2004) 1132-1136
10. Zelefsky M.J., Hunt M.A., Fuks Z., et al. 16: Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) S9
11. Chism D.B., Horwitz E.M., Hanlon A.L., et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 55 (2003) 71-77
12. Kuban D., Pollack A., Huang E., et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 1260-1268
13. Lawton C., Won M., Pilepich M., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 (1991) 935-939
14. Pilepich M.M.V., Krall J.J.M., Sause W.W.T., et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 13 (1987) 351-357
15. Smit W.W.G., Helle P.P.A., van Putten W.W.L., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 (1990) 23-29
16. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 2460-2468
17. Zelefsky M.J., Fuks Z.V.I., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
18. Burman C., Chui C.S., Kutcher G., et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39 (1997) 863-873
19. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 10 (2006) 82-86
20. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
21. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
22. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
23. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
24. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
25. Eade T.N., Hanlon A.L., Horwitz E.M., et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 682-689
26. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
27. Leibel S., Zelefsky M., Kutcher G., et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 152 (1994) 1792-1798
28. Zelefsky M.J., Fuks Z., Wolfe T., et al. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy-a dose-escalation study. Radiology 209 (1998) 169-174
29. Ling C.C., Burman C., Chui C.S., et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Physs 35 (1996) 721-730
30. Chui C.-S., and Spirou S.V. Inverse planning algorithms for external beam radiation therapy. Med Dosim 26 (2001) 189-197
31. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
32. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
33. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
34. Morgan P.B., Hanlon A.L., Horwitz E.M., et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1074-1081
35. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
36. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
37. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
38. Namiki S.S., Ishidoya S.S., Tochigi T.T., et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy. Jap J Clin Oncol 36 (2006) 224-230
39. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 160-166
40. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
41. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
42. Kupelian P.A., Buchsbaum J.C., Reddy C.A., et al. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason <= 6, and pretreatment prostate-specific antigen <= 10). Int J Radiat Oncol Biol Phys 50 (2001) 621-625
43. Symon Z., Griffith K.A., McLaughlin P.W., et al. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57 (2003) 384-390
44. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-108
45. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
46. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
47. Pilepich M.V., Sause W.T., Shipley W.U., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group. Urology 45 (1995) 616-623